Test drug HEC73543 against chemo for FLT3-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 3 study compares HEC73543 versus standard “salvage” chemotherapy in adults with AML that has come back or did not respond after first treatment. It’s designed for people whose leukemia has an FLT3-ITD mutation and may help improve response and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older when you sign consent.
- You have AML, either from starting in the blood/bone marrow (primary) or AML related to MDS.
- Your AML is resistant to treatment or has relapsed after your first-line AML therapy (even if you had a stem cell transplant).
- Your test results must show the FLT3 mutation—specifically FLT3-ITD—on a central lab blood or bone marrow sample.
- Your day-to-day function must be fairly good (ECOG score 0–2).
- Your doctor must think you can safely receive the planned rescue/salvage chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a new combination of medications against a standard treatment for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3-ITD mutation. The goal is to find out if the new combination works better and has fewer side effects. If you have this type of AML, you might be able to join and get access to newer drugs.
This study tests clifutinib (a targeted medicine) combined with chemotherapy in people newly diagnosed with AML. It aims to see if this combination is safer and more effective, including in older adults and people who may not tolerate strong chemotherapy.
This trial tests a targeted therapy that specifically attacks leukemia cells with the FLT3-ITD gene change. If you have this mutation, the goal is to see if adding this drug to standard chemotherapy improves your chances of going into remission.
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
This trial tests a three-drug combination for people with acute myeloid leukemia (AML) that did not respond to or came back after previous treatment with azacitidine and venetoclax. The goal is to see if adding gilteritinib can help control the leukemia.
Hear when a new Leukemia Acute Myeloid - AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.